Prevalence of Tardive Dyskinesia in an Electronic Medical Record Study at a Large Community Mental Health Treatment Center

North, Carol S.; McDonald, Katy; Hunter, Judith; Burruss, John

doi:10.4088/pcc.21m03069

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings reinforce the importance of clinicians routinely gathering information from patients about any symptoms, for example by using self-assessment screening tools, and asking about the impact these are having on their daily lives. However, data from a recent US survey of electronic medical records at a large community mental health treatment center suggest that routine screening for abnormal involuntary movements in APD-treated patients using validated scales, such as AIMS, can be low ( 112 ). Another US study found that implementing a 1-h training course for clinicians regarding AIMS screening for TD significantly improved the use of the tool and subsequent documentation in patients' records ( 113 ).…”

Section: Strategies For Minimizing and Managing Tdmentioning

confidence: 99%

Tardive dyskinesia in Asia— current clinical practice and the role of neurologists in the care pathway

Bhidayasiri,

Phokaewvarangkul,

Shang

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a movement disorder that can arise as a side effect of treatment with dopamine receptor-blocking agents (DRBAs), including antipsychotic drugs (APDs) used to manage psychotic illnesses. Second-generation APDs (SGAs) are often preferred to first-generation drugs due to their lower propensity to cause TD, however many SGAs-treated patients still develop the condition. Although TD is a global health concern, evidence regarding the occurrence of TD and how it is managed in Asian countries is currently limited. This article reports the results of a systematic review of the published literature on TD focusing on its prevalence, types of patients, knowledge of the condition, causative factors, and usual treatment pathways in clinical practice in Asian countries. Epidemiological data suggest that the prevalence of TD is increasing globally due to an overall rise in APD use, contributing factors being polypharmacy with multiple APDs, the use of higher than necessary doses, and off-label use for non-psychotic indications. Although exact prevalence figures for TD in Asian countries are difficult to define, there is a similar pattern of rising APD use which will result in increasing numbers of TD patients in this region. These issues need to be addressed and strategies developed to minimize TD risk and manage this disabling condition which impacts patients' quality of life and daily functioning. To date, both research into TD has been predominantly psychiatry focused and the perspectives from neurologists regarding the clinical management of this challenging condition are scarce. However, neurologists have an essential role in managing the movement disorders manifestations that characterize TD. Optimum management of TD, therefore, should ideally involve collaboration between psychiatrists and neurologists in joint care pathways, wherever practical. Collaborative pathways are proposed in this article, and the challenges that will need to be addressed in Asian countries to improve the care of people with TD are highlighted, with a focus on the neurologist's viewpoint and the implications for the management of TD globally.

show abstract

Section: Strategies For Minimizing and Managing Tdmentioning

confidence: 99%